Andreas Wollenberg

Professor

Ludwig-Maximilians-Universität München

Germany

Research Interests

Explore related searches

Professors in Germany

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Professor Andreas Wollenberg is a faculty member at Ludwig Maximilian University of Munich, Germany. His research primarily focuses on atopic dermatitis, with recent publications addressing treatment safety, efficacy, and patient-reported outcomes. He has contributed to key guidelines and studies on the management of xerosis cutis in atopic conditions and has explored innovative techniques in dermatological surgeries.

Articles (20)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Collaborators (15)

Michael Cork

University of Sheffield

UNITED KINGDOM

Andreas Wollenberg

Research Interests

Explore related searches

Contact this professor

About

Articles (20)

European Guideline (EuroGuiDerm) on atopic eczema: Living update

Safety of tralokinumab in patients with moderate-to-severe atopic dermatitis followed for up to 4.5 years: an integrated analysis of 8 clinical trials

Basic Emollients for Xerosis Cutis in Atopic Dermatitis: A Review of Clinical Studies

Basic Emollients for the Management of Xerosis Cutis: Biophysical Properties, Clinical Evidence, and Practical Considerations

Predicting success with reduced dosing frequency of tralokinumab in patients with moderate-to-severe atopic dermatitis

Patient-reported burden in adults with atopic dermatitis: an international qualitative study

Publisher Correction: Patients with Moderate-to-Severe Atopic Dermatitis Maintain Stable Response with No or Minimal Fluctuations with 1 Year of Lebrikizumab Treatment

Patients with Moderate-to-Severe Atopic Dermatitis Maintain Stable Response with No or Minimal Fluctuations with 1 Year of Lebrikizumab Treatment

How to Understand Personalized Medicine in Atopic Dermatitis Nowadays?

Dupilumab improves patient-reported symptoms and health-related quality of life in children aged 6–11 years with severe atopic dermatitis

First update of the living European guideline (EuroGuiDerm) on atopic eczema

A detailed look at the European Medicines Agency's recommendations for use of Janus kinase inhibitors in patients with atopic dermatitis

Nipple eczema: A systematic review and practical recommendations

Skin microbiome dysbiosis and the role of Staphylococcus aureus in atopic dermatitis in adults and children: A narrative review

Efficacy and Microbiota Modulation Induced by LimpiAL 2.5%, a New Medical Device for the Inverse Psoriasis Treatment

Itching and treatments in atopic dermatitis (AD): results from the German AD registry TREATgermany

Efficacy of downtitration or treatment withdrawal compared with continuous dosing after successful treatment with baricitinib in patients with moderate-to-severe atopic dermatitis in a randomized substudy from the long-term extension study BREEZE-AD3

Itching in Atopic Dermatitis: Patient- and Physician-reported Outcomes in the German Atopic Dermatitis Registry TREATgermany

The introduction of bedside ex vivo confocal microscopy during Mohs surgery of basal cell carcinoma: Patient and specialist benefit in an optimized healthcare environment

Atopic dermatitis: A global health perspective

Collaborators (15)

Michael Cork

Christian Apfelbacher

J. Gutermuth

Bernhard Homey

Mette Søndergaard Deleuran

John Su

Magdalena Trzeciak

Norito Katoh

Marco Alfio Cutuli

Di Marco Roberto (Maria Antonio)

Valerie Reynaert

Margitta Worm

Jacob Pontoppidan Thyssen

Charlotte G. Mortz

Alan Irvine

Make your next move.